Global Benign Prostatic Hyperplasia (BPH) Drugs Market Growth 2020-2025
According to this study, over the next five years the Benign Prostatic Hyperplasia (BPH) Drugs market will register a 1.0%% CAGR in terms of revenue, the global market size will reach $ 3376 million by 2025, from $ 3248.8 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Benign Prostatic Hyperplasia (BPH) Drugs business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Benign Prostatic Hyperplasia (BPH) Drugs, covering the supply chain analysis, impact assessment to the Benign Prostatic Hyperplasia (BPH) Drugs market size growth rate in several scenarios, and the measures to be undertaken by Benign Prostatic Hyperplasia (BPH) Drugs companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
The classification of Benign Prostatic Hyperplasia (BPH) Drugs includes Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors and Others. And the proportion of M Alpha-Blocker in 2019 is about 38%.
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospitals
Drugstores
Others
Benign Prostatic Hyperplasia (BPH) Drugs is widely used in Hospitals, Drugstores and Others. The most proportion of Benign Prostatic Hyperplasia (BPH) Drugs is used in Hospitals, and the proportion in 2019 is 48.97%.
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Eli Lilly
Novartis
GlaxoSmithKline
Sanofi
Pfizer
Astellas Pharma
TEVA
Abbott
Mylan
Allergan
Merck
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Benign Prostatic Hyperplasia (BPH) Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Benign Prostatic Hyperplasia (BPH) Drugs market by identifying its various subsegments.
Focuses on the key global Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Benign Prostatic Hyperplasia (BPH) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Benign Prostatic Hyperplasia (BPH) Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2015-2025
2.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
2.2.1 Alpha-Blocker
2.2.2 Phosphodiesterase Type-5 Inhibitors
2.2.3 Others
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2015-2020)
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Drugstores
2.4.3 Others
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
2.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2015-2020)
3 Global Benign Prostatic Hyperplasia (BPH) Drugs by Company
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2018-2020)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2018-2020)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2018-2020)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company
3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Benign Prostatic Hyperplasia (BPH) Drugs by Regions
4.1 Benign Prostatic Hyperplasia (BPH) Drugs by Regions
4.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
4.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
4.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
4.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
5 Americas
5.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries
5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2015-2020)
5.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
5.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Regions
6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Value by Regions (2015-2020)
6.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
6.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Countries
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2015-2020)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs by Countries
8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
10.3 Benign Prostatic Hyperplasia (BPH) Drugs Customer
11 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast
11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast (2021-2025)
11.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions
11.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions (2021-2025)
11.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type
11.8 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Application
12 Key Players Analysis
12.1 Eli Lilly
12.1.1 Company Information
12.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Eli Lilly Latest Developments
12.2 Novartis
12.2.1 Company Information
12.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.2.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Novartis Latest Developments
12.3 GlaxoSmithKline
12.3.1 Company Information
12.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 GlaxoSmithKline Latest Developments
12.4 Sanofi
12.4.1 Company Information
12.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Sanofi Latest Developments
12.5 Pfizer
12.5.1 Company Information
12.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Pfizer Latest Developments
12.6 Astellas Pharma
12.6.1 Company Information
12.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.6.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Astellas Pharma Latest Developments
12.7 TEVA
12.7.1 Company Information
12.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.7.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 TEVA Latest Developments
12.8 Abbott
12.8.1 Company Information
12.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.8.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Abbott Latest Developments
12.9 Mylan
12.9.1 Company Information
12.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Mylan Latest Developments
12.10 Allergan
12.10.1 Company Information
12.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.10.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Allergan Latest Developments
12.11 Merck
12.11.1 Company Information
12.11.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Merck Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Alpha-Blocker
Table 5. Major Players of Phosphodiesterase Type-5 Inhibitors
Table 6. Major Players of Others
Table 7. Global Consumption Sales by Type (2015-2020)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2015-2020)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2015-2020) ($ million)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Type (2015-2020) ($ Millions)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2015-2020)
Table 12. Global Consumption Sales by Application (2015-2020)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2015-2020)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Value by Application (2015-2020)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Application (2015-2020)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2015-2020)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2017-2019) (M Units)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2017-2019)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2017-2019) ($ Millions)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2017-2019)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company (2017-2019)
Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
Table 23. Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
Table 24. Benign Prostatic Hyperplasia (BPH) Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Regions 2015-2020 (M Units)
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Regions 2015-2020
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Value by Regions 2015-2020 ($ Millions)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Regions 2015-2020
Table 29. Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2015-2020) (M Units)
Table 30. Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries (2015-2020)
Table 31. Americas Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2015-2020) ($ Millions)
Table 32. Americas Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries (2015-2020)
Table 33. Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2015-2020) (M Units)
Table 34. Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2015-2020)
Table 35. Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2015-2020) (M Units)
Table 36. Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2015-2020)
Table 37. APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2015-2020) (M Units)
Table 38. APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries (2015-2020)
Table 39. APAC Benign Prostatic Hyperplasia (BPH) Drugs Value by Regions (2015-2020) ($ Millions)
Table 40. APAC Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Regions (2015-2020)
Table 41. APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2015-2020) (M Units)
Table 42. APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2015-2020)
Table 43. APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2015-2020) (M Units)
Table 44. APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2015-2020)
Table 45. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2015-2020) (M Units)
Table 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries (2015-2020)
Table 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2015-2020) ($ Millions)
Table 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries (2015-2020)
Table 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2015-2020) (M Units)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2015-2020)
Table 51. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2015-2020) (M Units)
Table 52. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2015-2020)
Table 53. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2015-2020) (M Units)
Table 54. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries (2015-2020)
Table 55. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2015-2020) ($ Millions)
Table 56. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2015-2020) (M Units)
Table 58. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2015-2020)
Table 59. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2015-2020) (M Units)
Table 60. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2015-2020)
Table 61. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 62. Benign Prostatic Hyperplasia (BPH) Drugs Customer List
Table 63. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast by Countries (2021-2025) (M Units)
Table 64. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Forecast by Regions
Table 65. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Countries (2021-2025) ($ Millions)
Table 66. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share Forecast by Regions
Table 67. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast by Type (2021-2025) (M Units)
Table 68. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share Forecast by Type (2021-2025)
Table 69. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Type (2021-2025) ($ Millions)
Table 70. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share Forecast by Type (2021-2025)
Table 71. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast by Application (2021-2025) (M Units)
Table 72. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share Forecast by Application (2021-2025)
Table 73. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Application (2021-2025) ($ Millions)
Table 74. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share Forecast by Application (2021-2025)
Table 75. Eli Lilly Product Offered
Table 76. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 77. Eli Lilly Main Business
Table 78. Eli Lilly Latest Developments
Table 79. Eli Lilly Basic Information, Company Total Revenue (in $ million), Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Novartis Product Offered
Table 81. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 82. Novartis Main Business
Table 83. Novartis Latest Developments
Table 84. Novartis Basic Information, Company Total Revenue (in $ million), Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. GlaxoSmithKline Product Offered
Table 86. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 87. GlaxoSmithKline Main Business
Table 88. GlaxoSmithKline Latest Developments
Table 89. GlaxoSmithKline Basic Information, Company Total Revenue (in $ million), Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. Sanofi Product Offered
Table 91. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 92. Sanofi Main Business
Table 93. Sanofi Latest Developments
Table 94. Sanofi Basic Information, Company Total Revenue (in $ million), Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. Pfizer Product Offered
Table 96. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 97. Pfizer Main Business
Table 98. Pfizer Latest Developments
Table 99. Pfizer Basic Information, Company Total Revenue (in $ million), Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Astellas Pharma Product Offered
Table 101. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 102. Astellas Pharma Main Business
Table 103. Astellas Pharma Latest Developments
Table 104. Astellas Pharma Basic Information, Company Total Revenue (in $ million), Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. TEVA Product Offered
Table 106. TEVA Basic Information, Company Total Revenue (in $ million), Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. TEVA Main Business
Table 108. TEVA Latest Developments
Table 109. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 110. Abbott Product Offered
Table 111. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 112. Abbott Main Business
Table 113. Abbott Latest Developments
Table 114. Abbott Basic Information, Company Total Revenue (in $ million), Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. Mylan Product Offered
Table 116. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 117. Mylan Main Business
Table 118. Mylan Latest Developments
Table 119. Mylan Basic Information, Company Total Revenue (in $ million), Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. Allergan Product Offered
Table 121. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 122. Allergan Main Business
Table 123. Allergan Latest Developments
Table 124. Allergan Basic Information, Company Total Revenue (in $ million), Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 125. Merck Product Offered
Table 126. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 127. Merck Main Business
Table 128. Merck Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 129. Merck Latest Developments
List of Figures
Figure 1. Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 2. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth Rate 2015-2025 (M Units)
Figure 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Alpha-Blocker
Figure 7. Product Picture of Phosphodiesterase Type-5 Inhibitors
Figure 8. Product Picture of Others
Figure 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2015-2020)
Figure 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Type (2015-2020)
Figure 11. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Hospitals
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Hospitals (2015-2020) (M Units)
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Hospitals (2015-2020) ($ Millions)
Figure 14. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Drugstores
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Drugstores (2015-2020) (M Units)
Figure 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Drugstores (2015-2020) ($ Millions)
Figure 17. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Others
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Others (2015-2020) (M Units)
Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Others (2015-2020) ($ Millions)
Figure 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2015-2020)
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Application (2015-2020)
Figure 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2017
Figure 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019
Figure 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company in 2017
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company in 2019
Figure 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company in 2019
Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Regions 2015-2020
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Regions 2015-2020
Figure 29. Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2015-2020 (M Units)
Figure 30. Americas Benign Prostatic Hyperplasia (BPH) Drugs Value 2015-2020 ($ Millions)
Figure 31. APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2015-2020 (M Units)
Figure 32. APAC Benign Prostatic Hyperplasia (BPH) Drugs Value 2015-2020 ($ Millions)
Figure 33. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2015-2020 (M Units)
Figure 34. Europe Benign Prostatic Hyperplasia (BPH) Drugs Value 2015-2020 ($ Millions)
Figure 35. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2015-2020 (M Units)
Figure 36. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value 2015-2020 ($ Millions)
Figure 37. Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2019
Figure 38. Americas Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries in 2019
Figure 39. Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2019
Figure 40. Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2019
Figure 41. United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 42. United States Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 43. Canada Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 44. Canada Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 45. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 46. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 47. APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2019
Figure 48. APAC Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Regions in 2019
Figure 49. APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2019
Figure 50. APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2019
Figure 51. China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 52. China Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 53. Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 54. Japan Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 55. Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 56. Korea Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 57. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 58. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 59. India Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 60. India Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 61. Australia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 62. Australia Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 63. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2019
Figure 64. Europe Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries in 2019
Figure 65. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2019
Figure 66. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2019
Figure 67. Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 68. Germany Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 69. France Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 70. France Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 71. UK Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 72. UK Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 73. Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 74. Italy Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 75. Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 76. Russia Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 77. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2019
Figure 78. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries in 2019
Figure 79. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2019
Figure 80. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2019
Figure 81. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 82. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 83. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 84. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 85. Israel Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 86. Israel Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 87. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 88. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 89. GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2015-2020 (M Units)
Figure 90. GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2015-2020 ($ Millions)
Figure 91. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth Rate Forecast (2021-2025) (M Units)
Figure 92. Global Benign Prostatic Hyperplasia (BPH) Drugs Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 93. Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 94. Americas Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 95. APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 96. APAC Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 97. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 98. Europe Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 99. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 100. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 101. United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 102. United States Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 103. Canada Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 104. Canada Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 105. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 106. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 107. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 108. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 109. China Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 110. China Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 111. Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 112. Japan Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 113. Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 114. Korea Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 115. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 116. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 117. India Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 118. India Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 119. Australia Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 120. Australia Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 121. Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 122. Germany Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 123. France Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 124. France Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 125. UK Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 126. UK Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 127. Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 128. Italy Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 129. Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 130. Russia Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 131. Spain Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 132. Spain Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 133. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 134. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 135. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 136. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 137. Israel Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 138. Israel Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 139. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 140. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 141. GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2021-2025 (M Units)
Figure 142. GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Value 2021-2025 ($ Millions)
Figure 143. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2018-2020)
Figure 144. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2018-2020)
Figure 145. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2018-2020)
Figure 146. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2018-2020)
Figure 147. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2018-2020)
Figure 148. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2018-2020)
Figure 149. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2018-2020)
Figure 150. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2018-2020)
Figure 151. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2018-2020)
Figure 152. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2018-2020)
Figure 153. Merck Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2018-2020)
